{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-077304","form_type":"8-K","ticker":"CPHI","cik":"0001106644","company_name":"CHINA PHARMA HOLDINGS, INC.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.627878+00:00","generated_at":"2026-06-21T10:04:43.512222+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"China Pharma receives NYSE American deficiency notice for equity shortfall","bullets":["Stockholders' equity of $2.8M as of Sept 30, 2022 below the $4.0M minimum required by Section 1003(a)(ii).","Company has reported net losses in four most recent fiscal years ended Dec 31, 2021.","Must regain compliance with equity standard by Dec 15, 2023, and price noncompliance by March 26, 2023.","NYSE American accepted a plan on Aug 29, 2022 to cure equity noncompliance; failure to progress may trigger delisting.","Common stock (CPHI) continues trading with .BC indicator while company attempts to cure deficiencies."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-077304","json":"https://secwatch.observer/filing/0001213900-22-077304.json","markdown":"https://secwatch.observer/filing/0001213900-22-077304.md","text":"https://secwatch.observer/filing/0001213900-22-077304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077304/0001213900-22-077304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077304/ea169585-8k_chinapharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:04:43.512222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7d1682ff9ba850ee9df07d24a8c4df7d8dc592d","claim":"CHINA PHARMA HOLDINGS, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).","evidence_excerpt":"if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that Company had stockholders’ equity of $2.8 million as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021. The Company remains","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390022077304/0001213900-22-077304-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nyse american"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"1003(a)(ii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}